Jefferies Financial Group Reaffirms “Buy” Rating for BioNTech (NASDAQ:BNTX)

BioNTech (NASDAQ:BNTX)‘s stock had its “buy” rating reiterated by analysts at Jefferies Financial Group in a research report issued to clients and investors on Wednesday,MarketScreener Latest Ratings reports. They currently have a $151.00 target price on the stock. Jefferies Financial Group’s target price indicates a potential upside of 56.10% from the stock’s current price.

A number of other analysts also recently issued reports on BNTX. Berenberg Bank restated a “buy” rating on shares of BioNTech in a report on Tuesday, November 25th. Wells Fargo & Company set a $150.00 price target on shares of BioNTech and gave the stock an “overweight” rating in a research note on Tuesday, August 5th. Morgan Stanley reissued an “overweight” rating and issued a $134.00 price objective on shares of BioNTech in a research note on Monday, November 3rd. UBS Group lifted their price objective on shares of BioNTech from $115.00 to $117.00 and gave the company a “neutral” rating in a report on Thursday, November 6th. Finally, HC Wainwright increased their target price on shares of BioNTech from $136.00 to $140.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Ten research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $136.42.

BioNTech Price Performance

NASDAQ:BNTX traded up $0.62 during trading hours on Wednesday, reaching $96.73. 3,482,761 shares of the company were exchanged, compared to its average volume of 949,347. BioNTech has a twelve month low of $81.20 and a twelve month high of $129.27. The stock’s 50-day moving average is $102.99 and its 200-day moving average is $105.26. The company has a current ratio of 7.12, a quick ratio of 7.02 and a debt-to-equity ratio of 0.01. The firm has a market cap of $21.78 billion, a PE ratio of -36.78 and a beta of 1.30.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, November 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.75 by ($0.89). BioNTech had a negative return on equity of 3.03% and a negative net margin of 17.91%.The business had revenue of $1.78 billion for the quarter, compared to analysts’ expectations of $1.21 billion. During the same period in the previous year, the company earned $0.81 EPS. BioNTech’s quarterly revenue was up 22.0% compared to the same quarter last year. On average, sell-side analysts anticipate that BioNTech will post -3.88 earnings per share for the current fiscal year.

Institutional Trading of BioNTech

Several large investors have recently added to or reduced their stakes in the business. Baader Bank Aktiengesellschaft lifted its position in BioNTech by 6.3% during the 2nd quarter. Baader Bank Aktiengesellschaft now owns 151,862 shares of the company’s stock worth $16,032,000 after acquiring an additional 9,040 shares during the last quarter. Shell Asset Management Co. increased its stake in shares of BioNTech by 15.3% in the second quarter. Shell Asset Management Co. now owns 40,610 shares of the company’s stock worth $4,324,000 after purchasing an additional 5,398 shares during the period. Swedbank AB acquired a new position in shares of BioNTech during the 1st quarter worth about $3,415,000. Millennium Management LLC lifted its position in shares of BioNTech by 252.5% in the 1st quarter. Millennium Management LLC now owns 544,970 shares of the company’s stock worth $49,625,000 after acquiring an additional 390,360 shares during the period. Finally, Allianz SE lifted its position in shares of BioNTech by 635.0% during the 2nd quarter. Allianz SE now owns 5,880 shares of the company’s stock worth $626,000 after buying an additional 5,080 shares during the period. 15.52% of the stock is owned by institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.